中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 6
Jun.  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(6): 1481-1488

Application of liquid biopsy in early screening and diagnosis of pancreatic cancer

DOI: 10.12449/JCH260636

  • Department of General Surgery，Xijing Hospital，Air Force Medical University，Xi’an 710032，China

Research funding:

Shaanxi Provincial Key Research and Development Program (S2023-YF-YBSF-1094);

Talent-Driven Innovation Program of Xijing Hospital, Air Force Medical University (XJZT24CY60)

More Information
  • Corresponding author: LIU Zhengcai， xjgdwk@126.com （ORCID： 0000-0001-5046-440X）; YUE Shuqiang， blanker36@163.com （ORCID： 0009-0009-1191-7651）
  • Received Date: 2025-09-22
  • Accepted Date: 2025-12-10
  • Published Date: 2026-06-25
    Abstract
  • Pancreatic cancer is characterized by occult clinical manifestations and high malignancy， and conventional imaging examinations and carbohydrate antigen 19-9 lack sufficient sensitivity and specificity for detecting early-stage pancreatic cancer lesions. Difficulty in early diagnosis severely restricts the long-term survival of pancreatic cancer patients. Liquid biopsy targets the biomarkers in body fluid samples， including circulating tumor cells， circulating tumor DNA， circulating tumor microRNA， and extracellular vesicles， showing the advantages of noninvasiveness and continuous monitoring. This review systematically summarizes the latest advances in liquid biopsy for the early screening and diagnosis， recurrence prediction， and prognostic assessment of pancreatic cancer， aiming to provide new insights and references for precision screening of high-risk populations and the clinical translation of liquid biopsy.

     

    • FullText(HTML)
  • loading
    • References(54)
  • [1]
    FELISMINO TC, RODRIGUES D, BRITO A, et al. Evolving survival patterns in pancreatic adenocarcinoma: A 23-year retrospective observational analysis[J]. J Gastrointest Oncol, 2025, 16( 3): 1280- 1286. DOI: 10.21037/jgo-2024-942.
    [2]
    YI LX, FANG HL, LI JY, et al. Incidence and mortality of pancreatic cancer in the world and China in 2022[J]. Acad J Nav Med Univ, 2024, 45( 12): 1470- 1477. DOI: 10.16781/j.CN31-2187/R.20240630.

    易丽夏, 方涵露, 李婧怡, 等. 2022年全球和中国胰腺癌发病及死亡分析[J]. 海军军医大学学报, 2024, 45( 12): 1470- 1477. DOI: 10.16781/j.CN31-2187/R.20240630.
    [3]
    STOOP TF, JAVED AA, OBA A, et al. Pancreatic cancer[J]. Lancet, 2025, 405( 10485): 1182- 1202. DOI: 10.1016/S0140-6736(25)00261-2.
    [4]
    LIU WK, TANG BJ, WANG F, et al. Predicting early recurrence for resected pancreatic ductal adenocarcinoma: A multicenter retrospective study in China[J]. Am J Cancer Res, 2021, 11( 6): 3055- 3069.
    [5]
    BLACKFORD AL, CANTO MI, DBOUK M, et al. Pancreatic cancer surveillance and survival of high-risk individuals[J]. JAMA Oncol, 2024, 10( 8): 1087- 1096. DOI: 10.1001/jamaoncol.2024.1930.
    [6]
    ZHANG TP, YE LY, WANG YY. Development and practice of precise treatment of pancreatic cancer[J]. Chin J Dig Surg, 2025, 24( 5): 567- 573. DOI: 10.3760/cma.j.cn115610-20250411-00147.

    张太平, 叶力源, 王苑阳. 胰腺癌精准治疗的发展与实践[J]. 中华消化外科杂志, 2025, 24( 5): 567- 573. DOI: 10.3760/cma.j.cn115610-20250411-00147.
    [7]
    ZHENG BL, PENG J, MENG Y. Effect of KRAS gene mutation on clinical prognosis of resectable pancreatic cancer[J/OL]. Chin J Hepatic Surg(Electronic Edition), 2025, 14( 3): 456- 462. DOI: 10.3877/cma.j.issn.2095-3232.2025.03.019.

    郑秉礼, 彭洁, 孟塬. KRAS基因突变对可切除胰腺癌临床预后的影响[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14( 3): 456- 462. DOI: 10.3877/cma.j.issn.2095-3232.2025.03.019.
    [8]
    LILLY AC, ASTSATUROV I, GOLEMIS EA. Intrapancreatic fat, pancreatitis, and pancreatic cancer[J]. Cell Mol Life Sci, 2023, 80( 8): 206. DOI: 10.1007/s00018-023-04855-z.
    [9]
    PIAN LL, SONG MH, WANG TF, et al. Identification and analysis of pancreatic intraepithelial neoplasia: Opportunities and challenges[J]. Front Endocrinol, 2025, 15: 1401829. DOI: 10.3389/fendo.2024.1401829.
    [10]
    GARDNER TB, PARK WG, ALLEN PJ. Diagnosis and management of pancreatic cysts[J]. Gastroenterology, 2024, 167( 3): 454- 468. DOI: 10.1053/j.gastro.2024.02.041.
    [11]
    BOJANAPU S, KASI A. Pancreatic mucinous cystadenoma(archived)[M]. Treasure Island(FL): StatPearls Publishing, 2025.
    [12]
    YACHIDA S, JONES S, BOZIC I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer[J]. Nature, 2010, 467( 7319): 1114- 1117. DOI: 10.1038/nature09515.
    [13]
    YAMAO K, TSURUSAKI M, TAKASHIMA K, et al. Analysis of progression time in pancreatic cancer including carcinoma in situ based on magnetic resonance cholangiopancreatography findings[J]. Diagnostics, 2021, 11( 10): 1858. DOI: 10.3390/diagnostics11101858.
    [14]
    SAGAMI R, YAMAO K, NAKAHODO J, et al. Pre-operative imaging and pathological diagnosis of localized high-grade pancreatic intra-epithelial neoplasia without invasive carcinoma[J]. Cancers, 2021, 13( 5): 945. DOI: 10.3390/cancers13050945.
    [15]
    HELLER M, MANN DA, KATONA BW. Current approaches of pancreatic cancer surveillance in high-risk individuals[J]. J Gastrointest Cancer, 2025, 56( 1): 61. DOI: 10.1007/s12029-025-01184-1.
    [16]
    Pancreatic Disease Collaborative Group, Chinese Society of Digestive Endoscopy. Chinese consensus on the early screening and surveillance for pancreatic cancer in high-risk individuals(2021, Nanjing)[J]. J Clin Hepatol, 2022, 38( 5): 1016- 1022. DOI: 10.3969/j.issn.1001-5256.2022.05.008.

    中华医学会消化内镜学分会胰腺疾病协作组. 中国胰腺癌高危人群早期筛查和监测共识意见(2021, 南京)[J]. 临床肝胆病杂志, 2022, 38( 5): 1016- 1022. DOI: 10.3969/j.issn.1001-5256.2022.05.008.
    [17]
    ZHAO J, WANG JH, GU YL, et al. Diagnostic methods for pancreatic cancer and their clinical applications(Review)[J]. Oncol Lett, 2025, 30( 1): 370. DOI: 10.3892/ol.2025.15116.
    [18]
    PAWELEC N, DURKO Ł, MAŁECKA-WOJCIESKO E. Changes connected to early chronic pancreatitis and early pancreatic cancer in endoscopic ultrasonography(EUS): Clinical implications[J]. Cancers, 2025, 17( 11): 1891. DOI: 10.3390/cancers17111891.
    [19]
    OHTSUKA T, FERNANDEZ-DEL CASTILLO C, FURUKAWA T, et al. International evidence-based Kyoto guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas[J]. Pancreatology, 2024, 24( 2): 255- 270. DOI: 10.1016/j.pan.2023.12.009.
    [20]
    JUNG P, KIM S, HYUN C, et al. Imaging-based surveillance in patients with initially detected pancreatic cystic lesions[J]. Eur J Radiol, 2025, 187: 112102. DOI: 10.1016/j.ejrad.2025.112102.
    [21]
    PIENKOWSKI T, WAWRZAK-PIENKOWSKA K, TANKIEWICZ-KWEDLO A, et al. Leveraging glycosylation for early detection and therapeutic target discovery in pancreatic cancer[J]. Cell Death Dis, 2025, 16( 1): 227. DOI: 10.1038/s41419-025-07517-z.
    [22]
    ZHU ZX, ZHANG YX, ZHANG WJ, et al. High-throughput enrichment of portal venous circulating tumor cells for highly sensitive diagnosis of CA19-9-negative pancreatic cancer patients using inertial microfluidics[J]. Biosens Bioelectron, 2024, 259: 116411. DOI: 10.1016/j.bios.2024.116411.
    [23]
    EISSA MAL, LERNER L, ABDELFATAH E, et al. Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood[J]. Clin Epigenetics, 2019, 11( 1): 59. DOI: 10.1186/s13148-019-0650-0.
    [24]
    XIN WP, TU SJ, YI SQ, et al. Clinical significance of tumor suppressor genes methylation in circulating tumor DNA of patients with pancreatic cancer[J]. Gene, 2024, 897: 148078. DOI: 10.1016/j.gene.2023.148078.
    [25]
    NAKAMURA K, ZHU ZX, ROY S, et al. An exosome-based transcriptomic signature for noninvasive, early detection of patients with pancreatic ductal adenocarcinoma: A multicenter cohort study[J]. Gastroenterology, 2022, 163( 5): 1252- 1266.e2. DOI: 10.1053/j.gastro.2022.06.090.
    [26]
    HE XM, CHEN LT, DI Y, et al. Plasma-derived exosomal long noncoding RNAs of pancreatic cancer patients as novel blood-based biomarkers of disease[J]. BMC Cancer, 2024, 24( 1): 961. DOI: 10.1186/s12885-024-12755-z.
    [27]
    DAVID P, KOUHESTANI D, HANSEN FJ, et al. Exosomal CD40, CD25, and serum CA19-9 as combinatory novel liquid biopsy biomarker for the diagnosis and prognosis of patients with pancreatic ductal adenocarcinoma[J]. Int J Mol Sci, 2025, 26( 4): 1500. DOI: 10.3390/ijms26041500.
    [28]
    RING A, NGUYEN-STRÄULI BD, WICKI A, et al. Biology, vulnerabilities and clinical applications of circulating tumour cells[J]. Nat Rev Cancer, 2023, 23( 2): 95- 111. DOI: 10.1038/s41568-022-00536-4.
    [29]
    SUN YF, ZHOU J, FAN J, et al. Single-cell RNA sequencing reveals spatial heterogeneity and immune evasion of circulating tumor cells[J]. Cancer Biol Med, 2021, 18( 4): 934- 936. DOI: 10.20892/j.issn.2095-3941.2021.0466.
    [30]
    YASUI K, SAITO T, UEDA S, et al. Sequential changes in circulating tumor cells in the peripheral blood of pancreatic cancer patients with preoperative chemotherapy using a new immunocytology-based, light microscopic CTC detection platform[J]. Diagnostics, 2025, 15( 6): 752. DOI: 10.3390/diagnostics15060752.
    [31]
    WANG Y, YU XJ, HARTMANN D, et al. Circulating tumor cells in peripheral blood of pancreatic cancer patients and their prognostic role: A systematic review and meta-analysis[J]. HPB, 2020, 22( 5): 660- 669. DOI: 10.1016/j.hpb.2019.11.003.
    [32]
    ZHANG ZH, BAO YW, ZHAO YJ, et al. Circulating tumor cells as potential prognostic biomarkers for early-stage pancreatic cancer: A systematic review and meta-analysis[J]. World J Clin Oncol, 2023, 14( 11): 504- 517. DOI: 10.5306/wjco.v14.i11.504.
    [33]
    JAVED AA, DING D, HASANAIN A, et al. Persistent circulating tumor cells at 1 year after oncologic resection predict late recurrence in pancreatic cancer[J]. Ann Surg, 2023, 277( 6): 859- 865. DOI: 10.1097/SLA.0000000000005708.
    [34]
    GÖTZE J, MEIßNER K, PEREIRA-VEIGA T, et al. Identification and characterization of tumor and stromal derived liquid biopsy analytes in pancreatic ductal adenocarcinoma[J]. J Exp Clin Cancer Res, 2025, 44( 1): 14. DOI: 10.1186/s13046-024-03262-x.
    [35]
    CHENG H, LUO GP, JIN KZ, et al. Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients[J]. Cancer Med, 2020, 9( 6): 2153- 2159. DOI: 10.1002/cam4.2895.
    [36]
    MA LW, GUO HL, ZHAO YX, et al. Liquid biopsy in cancer current: Status, challenges and future prospects[J]. Signal Transduct Target Ther, 2024, 9( 1): 336. DOI: 10.1038/s41392-024-02021-w.
    [37]
    HAO MD, YANG YZ, WANG MD, et al. Application strategy of circulating tumor DNA in entire process of precision medicine for hepatocellular carcinoma[J]. Chin J Dig Surg, 2025, 24( 1): 86- 92. DOI: 10.3760/cma.j.cn115610-20241224-00578.

    赫明达, 杨钰泽, 王明达, 等. 循环肿瘤DNA在肝细胞癌精准医疗全程中的应用策略[J]. 中华消化外科杂志, 2025, 24( 1): 86- 92. DOI: 10.3760/cma.j.cn115610-20241224-00578.
    [38]
    THEPAREE T, AKROUSH M, SABATINI LM, et al. Cell free DNA in patients with pancreatic adenocarcinoma: Clinicopathologic correlations[J]. Sci Rep, 2024, 14: 15744. DOI: 10.1038/s41598-024-65562-8.
    [39]
    SELLAHEWA R, MOGHADDAM SM, LUNDY J, et al. Circulating tumor DNA is an accurate diagnostic tool and strong prognostic marker in pancreatic cancer[J]. Pancreas, 2023, 52( 3): e188- e195. DOI: 10.1097/MPA.0000000000002239.
    [40]
    ALQAHTANI A, ALLOGHBI A, COFFIN P, et al. Prognostic utility of preoperative and postoperative KRAS-mutated circulating tumor DNA(ctDNA) in resected pancreatic ductal adenocarcinoma: A systematic review and meta-analysis[J]. Surg Oncol, 2023, 51: 102007. DOI: 10.1016/j.suronc.2023.102007.
    [41]
    YI JM, GUZZETTA AA, BAILEY VJ, et al. Novel methylation biomarker panel for the early detection of pancreatic cancer[J]. Clin Cancer Res, 2013, 19( 23): 6544- 6555. DOI: 10.1158/1078-0432.CCR-12-3224.
    [42]
    KATHURIA-PRAKASH N, DAVE P, GARCIA L, et al. microRNAs in genitourinary malignancies: An exciting frontier of cancer diagnostics and therapeutics[J]. Int J Mol Sci, 2024, 25( 17): 9499. DOI: 10.3390/ijms25179499.
    [43]
    BESTARI MB, JOEWONO IR, SYAM AF. A quest for survival: A review of the early biomarkers of pancreatic cancer and the most effective approaches at present[J]. Biomolecules, 2024, 14( 3): 364. DOI: 10.3390/biom14030364.
    [44]
    TREEKITKARNMONGKOL W, DAI JL, LIU SY, et al. Blood-based microRNA biomarker signature of early-stage pancreatic ductal adenocarcinoma with lead-time trajectory in prediagnostic samples[J]. Gastro Hep Adv, 2024, 3( 8): 1098- 1115. DOI: 10.1016/j.gastha.2024.08.002.
    [45]
    BUCHHOLZ M, LAUSSER L, SCHENK M, et al. Combined analysis of a serum mRNA/miRNA marker signature and CA 19-9 for timely and accurate diagnosis of recurrence after resection of pancreatic ductal adenocarcinoma: A prospective multicenter cohort study[J]. United European Gastroenterol J, 2025, 13( 3): 353- 363. DOI: 10.1002/ueg2.12676.
    [46]
    KALLURI R, LEBLEU VS. The biology, function, and biomedical applications of exosomes[J]. Science, 2020, 367( 6478): eaau6977. DOI: 10.1126/science.aau6977.
    [47]
    TONG XY, TAN K, BAI LL, et al. Application of exosomes in diagnosis and treatment of hepatocellular carcinoma[J/OL]. Chin J Hepatic Surg(Electronic Edition), 2024, 13( 3): 384- 388. DOI: 10.3877/cma.j.issn.2095-3232.2024.03.021.

    仝心语, 谭凯, 白亮亮, 等. 外泌体在肝细胞癌诊疗中的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13( 3): 384- 388. DOI: 10.3877/cma.j.issn.2095-3232.2024.03.021.
    [48]
    WANG FB, WANG CB, CHEN SH, et al. Identification of blood-derived exosomal tumor RNA signatures as noninvasive diagnostic biomarkers for multi-cancer: A multi-phase, multi-center study[J]. Mol Cancer, 2025, 24( 1): 60. DOI: 10.1186/s12943-025-02271-4.
    [49]
    YANG G, QIU JD, XU JW, et al. Using a microRNA panel of circulating exosomes for diagnosis of pancreatic cancer: Multicentre case-control study[J]. Br J Surg, 2023, 110( 8): 908- 912. DOI: 10.1093/bjs/znac375.
    [50]
    ENGELS MML, BERGER CK, MAHONEY DW, et al. Multimodal pancreatic cancer detection using methylated DNA biomarkers in pancreatic juice and plasma CA 19-9: A prospective multicenter study[J]. Clin Gastroenterol Hepatol, 2025, 23( 5): 766- 775. DOI: 10.1016/j.cgh.2024.07.048.
    [51]
    BABA S, KAWASAKI T, HIRANO S, et al. A noninvasive urinary microRNA-based assay for the detection of pancreatic cancer from early to late stages: A case control study[J]. EClinicalMedicine, 2024, 78: 102936. DOI: 10.1016/j.eclinm.2024.102936.
    [52]
    ITO T, IWASAWA T, SAKURABA S, et al. Plasma and urine circulating tumor DNA methylation profiles for non-invasive pancreatic ductal adenocarcinoma detection: Significant findings in plasma only[J]. Int J Mol Sci, 2025, 26( 11): 4972. DOI: 10.3390/ijms26114972.
    [53]
    YEO D, BASTIAN A, STRAUSS H, et al. Exploring the clinical utility of pancreatic cancer circulating tumor cells[J]. Int J Mol Sci, 2022, 23( 3): 1671. DOI: 10.3390/ijms23031671.
    [54]
    VELPULA T, BUDDOLLA V. Enhancing detection and monitoring of circulating tumor cells: Integrative approaches in liquid biopsy advances[J]. J Liq Biopsy, 2025, 8: 100297. DOI: 10.1016/j.jlb.2025.100297.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (59) PDF downloads(18) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return